These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2182974)

  • 1. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
    Illingworth DR; O'Malley JP
    Metabolism; 1990 Apr; 39(4):403-9. PubMed ID: 2182974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
    Larsen ML; Illingworth DR; O'Malley JP
    Atherosclerosis; 1994 Apr; 106(2):235-40. PubMed ID: 8060383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia.
    Hoogwerf BJ; Peters JR; Frantz ID; Hunninghake DB
    Metabolism; 1985 Oct; 34(10):978-81. PubMed ID: 4046841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
    Illingworth DR; Bacon S
    Circulation; 1989 Mar; 79(3):590-6. PubMed ID: 2645064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
    Feussner G; Eichinger M; Ziegler R
    Clin Investig; 1992 Nov; 70(11):1027-35. PubMed ID: 1472833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
    Stuyt PM; Mol MJ; Stalenhoef AF; Demacker PN; Van 't Laar A
    Am J Med; 1990 Jan; 88(1N):42N-45N. PubMed ID: 2368763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
    Vega GL; East C; Grundy SM
    Atherosclerosis; 1988 Mar; 70(1-2):131-43. PubMed ID: 3162680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.
    Crouse JR; Grundy SM
    Metabolism; 1981 Feb; 30(2):123-8. PubMed ID: 7464561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients.
    Dujovne CA; Azarnoff DL; Pentikainen P; Manion CV; Hurwitz A
    Am J Med Sci; 1979; 277(3):255-61. PubMed ID: 222145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
    Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM.
    Garg A; Grundy SM
    Diabetes; 1989 Mar; 38(3):364-72. PubMed ID: 2917701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial vitamin A and squalene clearances and cholesterol synthesis off and on lovastatin treatment in type III hyperlipoproteinemia.
    Gylling H; Relas H; Miettinen TA
    Atherosclerosis; 1995 May; 115(1):17-26. PubMed ID: 7669084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of lovastatin on concentrations and composition of lipoprotein subfractions.
    Nozaki S; Vega GL; Haddox RJ; Dolan ET; Grundy SM
    Atherosclerosis; 1990 Oct; 84(2-3):101-10. PubMed ID: 2282090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria.
    Golper TA; Illingworth DR; Morris CD; Bennett WM
    Am J Kidney Dis; 1989 Apr; 13(4):312-20. PubMed ID: 2650539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
    Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO
    Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.